

INFORMATION DISCLOSURE STATEMENT PTO-1449 DEC 12 2003 U.S. PATENT & TRADEMARK OFFICE		ATTY. DOCKET NO.		SERIAL NO.			
		39750-0006P1		10/666,927			
		APPLICANT John C. Prescott, et al.					
		FILING DATE Sept. 17, 2003		GROUP: Unknown			
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
JL	*6,335,155	1/1/02	Wells, J., et al.	435	4		
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
JL	*WO 03/046200	6/05/03	PCT	C12Q		<input type="checkbox"/>	<input type="checkbox"/>
JL	*WO 02/42773	5/30/02	PCT	G01N		<input type="checkbox"/>	<input type="checkbox"/>
JL	*WO 03/014308	2/20/03	PCT	C12N		<input type="checkbox"/>	<input type="checkbox"/>
JL	*WO 03/014072	2/20/03	PCT	C07C		<input type="checkbox"/>	<input type="checkbox"/>
JL	*WO 00/00823	1/06/00	PCT	G01N		<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
JL	*Erlanson, Daniel A., et al., "Site-directed ligand discovery", PNAS, 97, (17), 2000, pp. 9367-9372.						
JL	*Schindler, Thomas, et al., "Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase", Science, 289, 2000, pp. 1938-1942.						
JL	*Dudley, David T., et al., "A synthetic inhibitor of the mitogen-activated protein kinase cascade", Proc. Natl. Acad. Sci. USA, 92, 1995, pp. 7686-7689.						
JL	*Sebolt-Leopold, Judith S., et al., "Blockade of the MAP kinase pathway suppresses growth of colon tumors <i>in vivo</i> ", Nature Medicine, 5, (7), 1999, pp. 810-816.						
JL	*Sebolt-Leopold, Judith, et al., "Development of anticancer drugs targeting the MAP kinase pathway", Oncogene, 19, 2000, pp. 6594-6599.						
JL	*Pargellis, Christopher, et al., "Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site", Nature Structural Biology, 9, (4), 2002, pp. 268-272.						
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449 DEC 12 2003 U.S. PATENT & TRADEMARK OFFICE		ATTY. DOCKET NO. 39750-0006P1	SERIAL NO. 10/666,927				
APPLICANT John C. Prescott, et al.							
FILING DATE Sept. 17, 2003		GROUP: Unknown					
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	*Huse, Morgan, et al., "The Conformational Plasticity of Protein Kinases", Cell, 109, 2002, pp. 275-282.						
	*Regan, John, et al., "Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate", Journal of Medical Chemistry, 45, (14), 2002, pp. 2994-3008.						
	*Taylor, Susan S., et al., "Protein kinase inhibition: natural and synthetic variations on a theme", Current Opinion in Chemical Biology, 1, 1997, pp. 219-226.						
	*Johnson, Louise N., et al., "Structural Basis for Control by Phosphorylation", Chemical Reviews, 101, (8), 2001, pp. 2209-2242.						
	*Dancey, Janet, et al., "Issues and Progress with Protein Kinase Inhibitors for Cancer Treatment", Nature Reviews-Drug Discovery, 2, 2003, pp. 296-313.						
	*Cohen, Philip, "Protein kinases-the major drug targets of the twenty-first century?", Nature Reviews-Drug Discovery, 1, 2002, pp. 309-315.						
EXAMINER /Jeffrey Lundgren/ DATE CONSIDERED 09/18/2006							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.